Evidence map›Paper›PMID 39048762›Full record

GuidelineSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

MASCC/ISOO Clinical Practice Statement: The risk of secondary oral cancer following hematopoietic cell transplantation.

Judith E Raber-Durlacher, Nathaniel S Treister, Yehuda Zadik, David R Dean, Wanessa Miranda-Silva, Eduardo R Fregnani, Joel B Epstein, Sharon Elad

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. MASCC/ISOO Clinical Practice Statement: Management of oral manifestations of chronic graft-versus-host-disease.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Guideline
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Judith E Raber-DurlacherDepartment of Oral Medicine, Academic Center for Dentistry Amsterdam (ACTA), Department of Oral and Maxillofacial Surgery, Amsterdam UMC, University of Amsterdam and VU University, University of Amsterdam, Gustav Mahlerlaan 3004, 1081 LA, Amsterdam, The Netherlands. j.raber.durlacher@acta.nl.
Nathaniel S TreisterDivision of Oral Medicine and Dentistry Brigham and Women's Hospital and Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA.
Yehuda ZadikDepartment of Oral Medicine and Saligman Clinics, Faculty of Dental Medicine, The Hebrew University of Jerusalem, and Hadassah Medical Center, Jerusalem, Israel.
David R DeanDepartment of Oral Medicine, University of Washington School of Dentistry and Fred Hutchinson Cancer Center, Seattle, WA, USA.
Wanessa Miranda-SilvaCentro de Oncologia Molecular, Instituto de Ensino e Pesquisa, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
Eduardo R FregnaniCentro de Oncologia Molecular, Instituto de Ensino e Pesquisa, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
Joel B EpsteinDental Oncology Service, City of Hope Comprehensive Cancer Center, Duarte, CA and Cedars-Sinai Health System, Los Angeles, CA, USA.
Sharon EladOral Medicine, Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeA MASCC/ISOO Clinical Practice Statement (CPS) is aimed at generating a concise tool for clinicians that concentrates practical information needed for the management of oral complications of cancer patients. This CPS is focused on the risk of secondary oral cancer following hematopoietic cell transplantation (HCT).

methodsThis CPS was developed based on critical evaluation of the literature followed by a structured discussion of a group of leading experts, members of the Oral Care Study Group of MASCC/ISOO. The information is presented in the form of succinct bullets to generate a short manual about the best standard of care.

resultsStudies described a 7-16-fold higher risk of secondary oral cancer (mainly squamous cell carcinoma) in allogeneic HCT (alloHCT) recipients, particularly in those who developed chronic graft versus host disease (cGVHD). Risk increases over time and is influenced by several risk factors. In autologous HCT, oral cancer risk seemed only slightly elevated.

conclusionClinicians should be aware of the higher oral cancer risk in alloHCT survivors, and emphasize the importance of lifelong oral cancer surveillance (at least every 6-12 months) and avoiding cancer promoting lifestyle factors in an empathic way, particularly of those with (a history of) cGVHD. Post-HCT for Fanconi anemia or dyskeratosis congenita, education and rigorous follow-up is even more crucial. In case of suspected oral lesions in the presence of oral mucosal cGVHD, a GVHD intervention may facilitate diagnosis. Suspected lesions should be biopsied. More research is needed on the role of HPV in oral cancer post-HCT.

Indexed as

Carcinoma, Squamous CellHematopoietic Stem Cell TransplantationMouth NeoplasmsGraft vs Host DiseaseHumansNeoplasms, Second PrimaryReview Literature as TopicRisk FactorsGraft versus host diseaseHematopoietic cell transplantationOral careRisk factorsSecondary oral cancer

Identifiers

PMID39048762
PMCPMC11269467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.